BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

256 related articles for article (PubMed ID: 30504310)

  • 21. Paediatric Strategy Forum for medicinal product development of chimeric antigen receptor T-cells in children and adolescents with cancer: ACCELERATE in collaboration with the European Medicines Agency with participation of the Food and Drug Administration.
    Pearson AD; Rossig C; Mackall C; Shah NN; Baruchel A; Reaman G; Ricafort R; Heenen D; Bassan A; Berntgen M; Bird N; Bleickardt E; Bouchkouj N; Bross P; Brownstein C; Cohen SB; de Rojas T; Ehrlich L; Fox E; Gottschalk S; Hanssens L; Hawkins DS; Horak ID; Taylor DH; Johnson C; Karres D; Ligas F; Ludwinski D; Mamonkin M; Marshall L; Masouleh BK; Matloub Y; Maude S; McDonough J; Minard-Colin V; Norga K; Nysom K; Pappo A; Pearce L; Pieters R; Pule M; Quintás-Cardama A; Richardson N; Schüßler-Lenz M; Scobie N; Sersch MA; Smith MA; Sterba J; Tasian SK; Weigel B; Weiner SL; Zwaan CM; Lesa G; Vassal G
    Eur J Cancer; 2022 Jan; 160():112-133. PubMed ID: 34840026
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Cost-effectiveness of chimeric antigen receptor T-cell therapy in adults with relapsed or refractory follicular lymphoma.
    Potnis KC; Di M; Isufi I; Gowda L; Seropian SE; Foss FM; Forman HP; Huntington SF
    Blood Adv; 2023 Mar; 7(5):801-810. PubMed ID: 36342852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. ADCs, BiTEs, CARs, and Small Molecules: A New Era of Targeted Therapy in Non-Hodgkin Lymphoma.
    Abramson JS; Ghosh N; Smith SM
    Am Soc Clin Oncol Educ Book; 2020 May; 40():302-313. PubMed ID: 32421455
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Hematopoietic Cell Transplantation and Adoptive Cell Therapy in Peripheral T Cell Lymphoma.
    Rogers AM; Brammer JE
    Curr Hematol Malig Rep; 2020 Aug; 15(4):316-332. PubMed ID: 32529515
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Efficacy and safety-related factors of BTK inhibitors as a bridge to CAR-T therapy in R/R FL.
    Ye X; Fan X; Cui R; Mu J; Liu M; Lyu C; Li Y; Chen L; Zhang J; Li X; Wang J; Mou N; Deng Q
    Ann Hematol; 2023 Jul; 102(7):1789-1799. PubMed ID: 37171599
    [TBL] [Abstract][Full Text] [Related]  

  • 26. A Deep Insight Into CAR-T Cell Therapy in Non-Hodgkin Lymphoma: Application, Opportunities, and Future Directions.
    Marofi F; Rahman HS; Achmad MH; Sergeevna KN; Suksatan W; Abdelbasset WK; Mikhailova MV; Shomali N; Yazdanifar M; Hassanzadeh A; Ahmadi M; Motavalli R; Pathak Y; Izadi S; Jarahian M
    Front Immunol; 2021; 12():681984. PubMed ID: 34248965
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Ibrutinib improves the efficacy of anti-CD19-CAR T-cell therapy in patients with refractory non-Hodgkin lymphoma.
    Liu M; Deng H; Mu J; Li Q; Pu Y; Jiang Y; Deng Q; Qian Z
    Cancer Sci; 2021 Jul; 112(7):2642-2651. PubMed ID: 33932067
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Obinutuzumab combined with lenalidomide for relapsed or refractory follicular B-cell lymphoma (GALEN): a multicentre, single-arm, phase 2 study.
    Morschhauser F; Le Gouill S; Feugier P; Bailly S; Nicolas-Virelizier E; Bijou F; Salles GA; Tilly H; Fruchart C; Van Eygen K; Snauwaert S; Bonnet C; Haioun C; Thieblemont C; Bouabdallah R; Wu KL; Canioni D; Meignin V; Cartron G; Houot R
    Lancet Haematol; 2019 Aug; 6(8):e429-e437. PubMed ID: 31296423
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Allogeneic hematopoietic stem cell transplantation for relapsed follicular lymphoma: A combined analysis on behalf of the Lymphoma Working Party of the EBMT and the Lymphoma Committee of the CIBMTR.
    Sureda A; Zhang MJ; Dreger P; Carreras J; Fenske T; Finel H; Schouten H; Montoto S; Robinson S; Smith SM; Boumedil A; Hamadani M; Pasquini MC
    Cancer; 2018 Apr; 124(8):1733-1742. PubMed ID: 29424927
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Chimeric antigen receptor T-cell therapies for lymphoma.
    Brudno JN; Kochenderfer JN
    Nat Rev Clin Oncol; 2018 Jan; 15(1):31-46. PubMed ID: 28857075
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Thinking "outside the germinal center": Re-educating T cells to combat follicular lymphoma.
    Kambhampati S; Shouse G; Danilov AV
    Blood Rev; 2023 Sep; 61():101099. PubMed ID: 37173225
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Double-hit follicular lymphoma with MYC and BCL2 translocations: a study of 7 cases with a review of literature.
    Miao Y; Hu S; Lu X; Li S; Wang W; Medeiros LJ; Lin P
    Hum Pathol; 2016 Dec; 58():72-77. PubMed ID: 27544800
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Rituximab: a review of its use in non-Hodgkin's lymphoma and chronic lymphocytic leukaemia.
    Plosker GL; Figgitt DP
    Drugs; 2003; 63(8):803-43. PubMed ID: 12662126
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Low-grade lymphoma.
    Winter JN; Gascoyne RD; Van Besien K
    Hematology Am Soc Hematol Educ Program; 2004; ():203-20. PubMed ID: 15561684
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Manufacturing of gene-modified cytotoxic T lymphocytes for autologous cellular therapy for lymphoma.
    Cooper LJ; Ausubel L; Gutierrez M; Stephan S; Shakeley R; Olivares S; Serrano LM; Burton L; Jensen MC; Forman SJ; DiGiusto DL
    Cytotherapy; 2006; 8(2):105-17. PubMed ID: 16698684
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Clinical and Antitumor Immune Responses in Relapsed/Refractory Follicular Lymphoma Patients after Intranodal Injections of IFNα-Dendritic Cells and Rituximab: a Phase I Clinical Trial.
    Cox MC; Castiello L; Mattei M; Santodonato L; D'Agostino G; Muraro E; Martorelli D; Lapenta C; Di Napoli A; Di Landro F; Cangemi M; Pavan A; Castaldo P; Hohaus S; Donati S; Montefiore E; Berdini C; Carlei D; Monque DM; Ruco L; Prosperi D; Tafuri A; Spadaro F; Sestili P; Spada M; Dolcetti R; Santini SM; Rozera C; Aricò E; Capone I; Belardelli F
    Clin Cancer Res; 2019 Sep; 25(17):5231-5241. PubMed ID: 31171545
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Marrow-ablative treatment and autologous stem cell transplantation in follicular NHL.
    Bachy E; Salles G
    Best Pract Res Clin Haematol; 2011 Jun; 24(2):257-70. PubMed ID: 21658622
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Cost-effectiveness analysis of allogeneic versus autologous stem cell transplant versus chemo-immunotherapy for early relapse of follicular lymphoma within 2 years of initial therapy.
    Vijenthira A; Kuruvilla J; Prica A
    Bone Marrow Transplant; 2021 Oct; 56(10):2400-2409. PubMed ID: 33986499
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Hematopoietic cell transplantation for diffuse large B-cell and follicular lymphoma: Current controversies and advances.
    Epperla N; Hamadani M
    Hematol Oncol Stem Cell Ther; 2017 Dec; 10(4):277-284. PubMed ID: 28633038
    [TBL] [Abstract][Full Text] [Related]  

  • 40. CAR T-cell Therapy Yields Durable Remissions in FL.
    Cancer Discov; 2019 Sep; 9(9):OF4. PubMed ID: 31332022
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.